1. Home
  2. ARQT vs FIHL Comparison

ARQT vs FIHL Comparison

Compare ARQT & FIHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • FIHL
  • Stock Information
  • Founded
  • ARQT 2016
  • FIHL 2014
  • Country
  • ARQT United States
  • FIHL Bermuda
  • Employees
  • ARQT N/A
  • FIHL N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • FIHL
  • Sector
  • ARQT Health Care
  • FIHL
  • Exchange
  • ARQT Nasdaq
  • FIHL Nasdaq
  • Market Cap
  • ARQT 2.1B
  • FIHL 1.8B
  • IPO Year
  • ARQT 2020
  • FIHL 2023
  • Fundamental
  • Price
  • ARQT $20.86
  • FIHL $17.87
  • Analyst Decision
  • ARQT Strong Buy
  • FIHL Hold
  • Analyst Count
  • ARQT 7
  • FIHL 7
  • Target Price
  • ARQT $19.00
  • FIHL $20.71
  • AVG Volume (30 Days)
  • ARQT 2.0M
  • FIHL 437.1K
  • Earning Date
  • ARQT 10-28-2025
  • FIHL 11-12-2025
  • Dividend Yield
  • ARQT N/A
  • FIHL 3.35%
  • EPS Growth
  • ARQT N/A
  • FIHL N/A
  • EPS
  • ARQT N/A
  • FIHL N/A
  • Revenue
  • ARQT $263,464,999.00
  • FIHL $2,607,600,000.00
  • Revenue This Year
  • ARQT $72.46
  • FIHL $21.24
  • Revenue Next Year
  • ARQT $31.69
  • FIHL $5.01
  • P/E Ratio
  • ARQT N/A
  • FIHL N/A
  • Revenue Growth
  • ARQT 99.50
  • FIHL 21.21
  • 52 Week Low
  • ARQT $8.03
  • FIHL $14.17
  • 52 Week High
  • ARQT $21.84
  • FIHL $21.32
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 59.00
  • FIHL 49.53
  • Support Level
  • ARQT $20.34
  • FIHL $18.19
  • Resistance Level
  • ARQT $21.84
  • FIHL $19.06
  • Average True Range (ATR)
  • ARQT 1.09
  • FIHL 0.58
  • MACD
  • ARQT -0.00
  • FIHL -0.06
  • Stochastic Oscillator
  • ARQT 65.37
  • FIHL 44.29

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

Share on Social Networks: